Latest News about Phase 2 Trial
Recent news which mentions Phase 2 Trial
Clene Nanomedicine Presents Updated Data From Mid-Stage Amyotrophic Lateral Sclerosis Trials
March 14, 2022
Tickers
CLNN
From Benzinga
BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market
March 14, 2022
Tickers
BBIO
From Benzinga
Scholar Rock To Highlight Apitegromab Data From Ambulatory Cohort In Muscular Dystrophy
March 14, 2022
Tickers
SRRK
From Benzinga
Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer
February 17, 2022
Tickers
ALKS
From Benzinga
Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer
February 15, 2022
Tickers
AMGN
From Benzinga
From Benzinga
From Benzinga
Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration
February 14, 2022
Tickers
OPT
From Benzinga
RegenXBio Posts Updated Data From Hunter Syndrome Gene Therapy Trial
February 09, 2022
Tickers
RGNX
From Benzinga
4D Molecular Shares Updated Data From Fabry Disease Trial
February 09, 2022
Tickers
FDMT
From Benzinga
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
February 09, 2022
Tickers
AVRO
From Benzinga
Why Are NLS Pharmaceutics Shares Trading Higher During Premarket Monday?
February 07, 2022
Tickers
NLSP
From Benzinga
Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward
February 04, 2022
From Benzinga
Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity
January 31, 2022
Tickers
ALT
From Benzinga
From Benzinga
4D Pharma's Asthma Candidate Shows Positive Trends In Multiple Secondary Endpoints Of Efficacy
January 27, 2022
Tickers
LBPS
From Benzinga
Two Organizations To Support Wave Life Sciences' FTD, ALS Program
January 26, 2022
Tickers
WVE
From Benzinga
Imara To Start Testing Tovinontrine In Heart Failure Patients
January 25, 2022
Tickers
IMRA
From Benzinga
From Benzinga
89bio's NASH Candidate Shows Improvement In Disease Severity, Cardiovascular Health
January 25, 2022
Tickers
ETNB
From Benzinga
On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial
January 24, 2022
Tickers
SABS
From Benzinga
Mirati Therapeutics Posts 41% Objective Response Rate In Pretreated GI Cancer Patients
January 21, 2022
Tickers
MRTX
From Benzinga
Provention Bio Starts Mid-Stage Lupus Trial; Data Expected In 2024
January 21, 2022
Tickers
PRVB
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.